

# Maria Serena Longhi

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4554739/maria-serena-longhi-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

84  
papers

4,489  
citations

37  
h-index

66  
g-index

106  
ext. papers

5,387  
ext. citations

9.7  
avg, IF

5.61  
L-index

#	Paper	IF	Citations
84	The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. <i>Immunological Reviews</i> , <b>2017</b> , 276, 121-144	11.3	414
83	Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. <i>Journal of Hepatology</i> , <b>2004</b> , 41, 31-7	13.4	304
82	Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. <i>Journal of Immunology</i> , <b>2006</b> , 176, 4484-91	5.3	254
81	Regulatory T-cells in autoimmune diseases: challenges, controversies and--yet--unanswered questions. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 105-16	13.6	188
80	Autoimmune hepatitis. <i>Lancet, The</i> , <b>2013</b> , 382, 1433-44	40	177
79	Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. <i>Journal of Autoimmunity</i> , <b>2005</b> , 25, 63-71	15.5	162
78	Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. <i>Gastroenterology</i> , <b>2006</b> , 130, 868-82	13.3	150
77	Aetiopathogenesis of autoimmune hepatitis. <i>Journal of Autoimmunity</i> , <b>2010</b> , 34, 7-14	15.5	147
76	A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis. <i>Hepatology</i> , <b>2010</b> , 52, 999-1007	11.2	132
75	Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis. <i>Hepatology</i> , <b>2014</b> , 59, 1007-15	11.2	127
74	The metabolite BH4 controls T cell proliferation in autoimmunity and cancer. <i>Nature</i> , <b>2018</b> , 563, 564-568	50.4	103
73	Pathogenesis of autoimmune hepatitis. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2011</b> , 25, 653-64	2.5	102
72	Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. <i>Lancet Oncology, The</i> , <b>2002</b> , 3, 333-40	21.7	102
71	Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. <i>Hepatology</i> , <b>2007</b> , 46, 472-84	11.2	97
70	The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway. <i>Hepatology</i> , <b>2012</b> , 56, 677-86	11.2	94
69	Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. <i>Hepatology</i> , <b>2008</b> , 47, 581-91	11.2	88
68	CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 716-726	13.4	84

67	Diagnostic criteria of autoimmune hepatitis. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 435-40	13.6	83
66	Alginate microencapsulated hepatocytes optimised for transplantation in acute liver failure. <i>PLoS ONE</i> , <b>2014</b> , 9, e113609	3.7	83
65	Inhibition of interleukin-17 promotes differentiation of CD25 <sup>+</sup> cells into stable T regulatory cells in patients with autoimmune hepatitis. <i>Gastroenterology</i> , <b>2012</b> , 142, 1526-35.e6	13.3	82
64	Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis. <i>Hepatology</i> , <b>2011</b> , 53, 536-47	11.2	75
63	Autoimmune hepatitis. <i>Seminars in Immunopathology</i> , <b>2009</b> , 31, 421-35	12	75
62	Autoimmune hepatitis after liver transplantation. <i>Clinical Gastroenterology and Hepatology</i> , <b>2012</b> , 10, 346-53	6.9	68
61	Deletion of Lactate Dehydrogenase-A in Myeloid Cells Triggers Antitumor Immunity. <i>Cancer Research</i> , <b>2017</b> , 77, 3632-3643	10.1	67
60	In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression. <i>Hepatology</i> , <b>2015</b> , 62, 863-75	11.2	66
59	CD39 and CD161 modulate Th17 responses in Crohn's disease. <i>Journal of Immunology</i> , <b>2014</b> , 193, 3366-73	7.3	63
58	Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells. <i>Hepatology</i> , <b>2009</b> , 50, 130-42	11.2	61
57	Purinergic signaling during intestinal inflammation. <i>Journal of Molecular Medicine</i> , <b>2017</b> , 95, 915-925	5.5	55
56	Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states. <i>Journal of Molecular Medicine</i> , <b>2013</b> , 91, 165-72	5.5	52
55	Vitamin D levels in adults with Crohn's disease are responsive to disease activity and treatment. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 856-60	4.5	49
54	NADH oxidase-dependent CD39 expression by CD8(+) T cells modulates interferon gamma responses via generation of adenosine. <i>Nature Communications</i> , <b>2015</b> , 6, 8819	17.4	46
53	Regulatory T cells: Mechanisms of suppression and impairment in autoimmune liver disease. <i>IUBMB Life</i> , <b>2015</b> , 67, 88-97	4.7	45
52	CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease. <i>European Journal of Immunology</i> , <b>2012</b> , 42, 3062-72	6.1	45
51	Bilirubin suppresses Th17 immunity in colitis by upregulating CD39. <i>JCI Insight</i> , <b>2017</b> , 2,	9.9	45
50	Immune and viral profile from tolerance to hepatitis B surface antigen clearance: a longitudinal study of vertically hepatitis B virus-infected children on combined therapy. <i>Journal of Virology</i> , <b>2011</b> , 85, 2416-28	6.6	43

49	Characterization of human CD39+ Th17 cells with suppressor activity and modulation in inflammatory bowel disease. <i>PLoS ONE</i> , <b>2014</b> , 9, e87956	3.7	43
48	Review article: the modern management of autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 31, 771-87	6.1	41
47	T-regs in autoimmune hepatitis-systemic lupus erythematosus/mixed connective tissue disease overlap syndrome are functionally defective and display a Th1 cytokine profile. <i>Journal of Autoimmunity</i> , <b>2013</b> , 41, 146-51	15.5	36
46	The interplay between regulatory and effector T cells in autoimmune hepatitis: Implications for innovative treatment strategies. <i>Journal of Autoimmunity</i> , <b>2013</b> , 46, 74-80	15.5	33
45	Regulatory T-cell conditioning endows activated effector T cells with suppressor function in autoimmune hepatitis/autoimmune sclerosing cholangitis. <i>Hepatology</i> , <b>2017</b> , 66, 1570-1584	11.2	32
44	Purinergic signaling in liver disease. <i>Digestive Diseases</i> , <b>2014</b> , 32, 516-24	3.2	28
43	CD39 mediated regulation of Th17-cell effector function is impaired in juvenile autoimmune liver disease. <i>Journal of Autoimmunity</i> , <b>2016</b> , 72, 102-12	15.5	27
42	Ectonucleotidases in Intestinal and Hepatic Inflammation. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 507	8.4	23
41	Retinoic acid stabilizes antigen-specific regulatory T-cell function in autoimmune hepatitis type 2. <i>Journal of Autoimmunity</i> , <b>2014</b> , 53, 26-32	15.5	23
40	Human CD4+CD25(high)CD127 (low/neg) regulatory T cells. <i>Methods in Molecular Biology</i> , <b>2012</b> , 806, 287-99	1.4	23
39	Higher serum vitamin D levels are associated with protective serum cytokine profiles in patients with ulcerative colitis. <i>Cytokine</i> , <b>2018</b> , 103, 38-45	4	22
38	Regulatory T cells in autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 932-3; author reply 933-4	13.4	22
37	Cathelicidin Mediates a Protective Role of Vitamin D in Ulcerative Colitis and Human Colonic Epithelial Cells. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 885-897	4.5	21
36	HIF-1 $\beta$ induced xenobiotic transporters promote Th17 responses in Crohn's disease. <i>Journal of Autoimmunity</i> , <b>2018</b> , 94, 122-133	15.5	21
35	Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration. <i>Blood</i> , <b>2016</b> , 128, 563-73	2.2	19
34	The ectonucleotidase ENTPD1/CD39 limits biliary injury and fibrosis in mouse models of sclerosing cholangitis. <i>Hepatology Communications</i> , <b>2017</b> , 1, 957-972	6	19
33	Autoantibody and human leukocyte antigen profiles in children with autoimmune liver disease and their first-degree relatives. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2014</b> , 58, 457-62	2.8	18
32	Adaptive immunity in autoimmune hepatitis. <i>Digestive Diseases</i> , <b>2010</b> , 28, 63-9	3.2	17

31	Failure of lamivudine therapy for chemotherapy-induced reactivation of hepatitis B. <i>American Journal of Gastroenterology</i> , <b>2001</b> , 96, 1651-2	0.7	17
30	Immunosuppressive drugs affect interferon (IFN)- $\gamma$ and programmed cell death 1 (PD-1) kinetics in patients with newly diagnosed autoimmune hepatitis. <i>Clinical and Experimental Immunology</i> , <b>2017</b> , 189, 71-82	6.2	16
29	Selective deletion of ENTPD1/CD39 in macrophages exacerbates biliary fibrosis in a mouse model of sclerosing cholangitis. <i>Purinergic Signalling</i> , <b>2019</b> , 15, 375-385	3.8	13
28	Modulation of CD39 and Exogenous APT102 Correct Immune Dysfunction in Experimental Colitis and Crohn's Disease. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 818-830	1.5	13
27	Regulatory T cells in autoimmune hepatitis: an updated overview. <i>Journal of Autoimmunity</i> , <b>2021</b> , 119, 102619	15.5	13
26	Altered aryl-hydrocarbon-receptor signalling affects regulatory and effector cell immunity in autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 48-57	13.4	13
25	Expression of Ecto-nucleoside Triphosphate Diphosphohydrolases-2 and -3 in the Enteric Nervous System Affects Inflammation in Experimental Colitis and Crohn's Disease. <i>Journal of Crohns and Colitis</i> , <b>2017</b> , 11, 1113-1123	1.5	11
24	Novel high-throughput cell-based hybridoma screening methodology using the Celigo Image Cytometer. <i>Journal of Immunological Methods</i> , <b>2017</b> , 447, 23-30	2.5	10
23	Dysregulation of Adenosinergic Signaling in Systemic and Organ-Specific Autoimmunity. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	10
22	P2X7 receptor activation increases expression of caveolin-1 and formation of macrophage lipid rafts, thereby boosting CD39 activity. <i>Journal of Cell Science</i> , <b>2020</b> , 133,	5.3	8
21	Control of Gut Inflammation by Modulation of Purinergic Signaling. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 1882	8.4	7
20	Endogenous antisense RNA curbs CD39 expression in Crohn's disease. <i>Nature Communications</i> , <b>2020</b> , 11, 5894	17.4	7
19	Limited TCR repertoire and dysregulation mark late-stage COVID-19. <i>IScience</i> , <b>2021</b> , 24, 103205	6.1	6
18	Eosinophils and Purinergic Signaling in Health and Disease. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 1339	8.4	5
17	Human Leukocyte Antigen Profile Predicts Severity of Autoimmune Liver Disease in Children of European Ancestry. <i>Hepatology</i> , <b>2021</b> , 74, 2032-2046	11.2	5
16	Dysregulated Host Response in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Critical Illness. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab019	1	5
15	Autoimmune Hepatitis: Clinical Review with Insights into the Purinergic Mechanism of Disease. <i>Journal of Clinical and Translational Hepatology</i> , <b>2013</b> , 1, 79-86	5.2	4
14	Targeting ectonucleotidases to treat inflammation and halt cancer development in the gut. <i>Biochemical Pharmacology</i> , <b>2021</b> , 187, 114417	6	4

13	T helper cell immunity in pregnancy and influence on autoimmune disease progression. <i>Journal of Autoimmunity</i> , <b>2021</b> , 121, 102651	15.5	4
12	Ectonucleotidase Modulation of Lymphocyte Function in Gut and Liver. <i>Frontiers in Cell and Developmental Biology</i> , <b>2020</b> , 8, 621760	5.7	3
11	Reply: To PMID 23787765. <i>Hepatology</i> , <b>2015</b> , 61, 737-8	11.2	2
10	P15 Multiple defects of the immunoregulatory system contribute to the development of autoimmune hepatitis. <i>Gut</i> , <b>2011</b> , 60, A7-A7	19.2	1
9	Dysfunctional Immune Regulation in Autoimmune Hepatitis: From Pathogenesis to Novel Therapies. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 746436	8.4	1
8	P94 Rapamycin helps maintain the regulatory phenotype of cytochrome P450IID6-specific Treg expanded from patients with autoimmune hepatitis type 2 by reducing the number of IFN $\gamma$ cells. <i>Gut</i> , <b>2011</b> , 60, A43-A44	19.2	
7	P101 Regulatory T cells exhibit reduced phenotypic stability upon pro-inflammatory challenge in autoimmune hepatitis. <i>Gut</i> , <b>2011</b> , 60, A47-A47	19.2	
6	P04 A dose effect of the disease risk gene HLA DR3 contributes to numerical and functional impairment of CD4+CD25+ regulatory T cells in patients with autoimmune hepatitis. <i>Gut</i> , <b>2011</b> , 60, A2-A3 <sup>19.2</sup>	19.2	
5	PWE-041 Mannose binding lectin deficiency as a predictor of severity, disease progression and outcome following paracetamol-induced acute liver failure. <i>Gut</i> , <b>2010</b> , 59, A101.1-A101	19.2	
4	PMO-114 Low CD39 expression marks severe regulatory t cell impairment in patients with autoimmune sclerosing cholangitis. <i>Gut</i> , <b>2012</b> , 61, A119.1-A119	19.2	
3	Transcriptome profiling of PBMCs and formalin-fixed autopsy tissues from COVID-19 patients.. <i>STAR Protocols</i> , <b>2022</b> , 3, 101156	1.4	
2	P0161 PP CD4+CD25+ T REGS MAINTAIN THE ABILITY TO SUPPRESS CD4 T CELL FUNCTION IN PATIENTS WITH AUTOIMMUNE LIVER DISEASE. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2004</b> , 39, S119-S120	2.8	
1	Lymph Node Derived CLL Cells Have a More Activated Phenotype and Better Antigen Presentation Capabilities Compared To Those From The Peripheral Blood. <i>Blood</i> , <b>2013</b> , 122, 4119-4119	2.2	